Skip to main navigation Skip to search Skip to main content

A Multicentre, Parallel-group, Phase IIb, Randomised, Double-blind, Placebo-controlled, 4-Arm, 24-Week Study to Evaluate the Efficacy and Safety of AZD6793 Tablets in Adult Participants with Moderate to Very Severe Chronic Obstructive Pulmonary Disea

Project Details

StatusActive
Effective start/end date1/03/26 → 29/12/28

Funding

  • AstraZeneca: A$40,155.00